Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
Authors: Carausu Marcela , Carton Matthieu , Diéras Véronique , Petit Thierry , Guiu Séverine , Gonçalves Anthony , Augereau Paule , Ferrero Jean Marc , Levy Christelle , Ung Mony , Desmoulins Isabelle , Debled Marc , Bachelot Thomas , Pistilli Barbara , Frenel Jean-Sébastien , Mailliez Audrey , Chevrot Michaël , Cabel Luc 
Published: December 2022

ImportanceEvidence suggests that patients with human epidermal growth factor receptor 2–positive (ERBB2+ [formerly HER2+]) metastatic breast cancer (MBC) have different clinical characteristics and outcomes according to their hormone receptor (HR) status. The place of endocrine therapy (ET) for patients with HR+/ERBB2+ is still not clearly defined in this setting.ObjectiveTo evaluate the association of HR status and first-line inclusion of ET with outcomes among patients with ERBB2+ MBC.Design, Setting, and ParticipantsThis cohort study was an analysis of clinical data from the French clinical Epidemiological Strategy and Medical Economics (ESME) cohort, including patients with MBC who started treatment between 2008 and 2017. The last date of follow-up was June 18, 2020. Data were analyzed from May 2021 to May 2022.ExposuresPatients were treated with first-line ERBB2-targeted therapy and either chemotherapy (CT) with or without ET or ET alone. For the study of the association of maintenance ET with outcomes, we included patients treated with first-line ERBB2-targeted therapy with CT and with or without maintenance ET.Main Outcomes and MeasuresMedian overall survival (OS) and median first-line progression-free survival (PFS) were reported using the Kaplan-Meier method. Cox proportional hazards models and a propensity score were constructed to report and adjust for prognostic factors. Multivariable analysis included age at MBC, time to MBC, number of metastatic sites, type of metastases, and Eastern Cooperative Oncology Group performance status.ResultsAmong 4145 women with ERBB2+ MBC, 2696 patients had HR+ (median [IQR] age, 58.0 [47.0-67.0] years) and 1449 patients had HR– (56.0 [47.0-64.0] years) tumors. The median OS for patients with HR+ vs HR− tumors was 55.9 months (95% CI, 53.7-59.4 months) vs 42.0 months (95% CI, 38.8-45.2 months), confirmed in multivariable analysis (hazard ratio, 1.40; 95% CI, 1.26-1.56; P &amp;lt; .001). The median PFS for patients with HR+ vs HR− tumors was 12.2 months (95% CI, 11.5-12.9 months) vs 9.8 months (95% CI, 9.2-11.0 months; P = .01), and the HR was 1.15 (95% CI, 1.06-1.26; P &amp;lt; .001). In multivariable analysis, no significant difference was found in OS or PFS for 1520 patients treated with ERBB2-targeted therapy with CT and with or without ET vs 203 patients receiving ERBB2-targeted therapy with ET, regardless of type of ERBB2-targeted therapy (trastuzumab or trastuzumab with pertuzumab). This result was confirmed by matching patients using a propensity score. Using the time-dependent ET variable among patients with ERBB2-targeted therapy with CT, those with maintenance ET had significantly better PFS (hazard ratio, 0.70; 95% CI, 0.60-0.82; P &amp;lt; .001) and OS (hazard ratio, 0.47; 95% CI, 0.39-0.57; P &amp;lt; .001).Conclusions and RelevanceThese results suggest that ET-containing first-line regimens may be associated with benefits among a subgroup of patients with HR+/ERBB2+ MBC.